Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, received Health Canada approval for the first and only daily disposable contact lens for vision correction in patients who experience itchy allergy eyes due to allergic conjunctivitis: ACUVUE® Theravision™ with Ketotifen. The lens contains an H1 histamine receptor antagonist for the prevention of itchy allergy eyes associated with allergic conjunctivitis experienced by contact lens users to promote comfortable contact lens wear. In March 2021, ACUVUE® Theravision™ with Ketotifen received its first regulatory approval from the Japanese Ministry of Health, Labour and Welfare.
“We are proud to mark another step forward in delivering this important innovation to help relieve patients from allergic eye itch while continuing to comfortably wear contact lenses,” said Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision***. “We look forward to working with additional health authorities to make ACUVUE® Theravision™ with Ketotifen available to more patients around the world.”
Itchy allergy eyes can impact vision, and this becomes even more problematic for contact lens wearers – most of whom resort to rubbing their eyes.ǂ Data show that nearly 8 out of 10 contact lens wearers feel frustrated when their eye allergies interfere with normal contact lens wear.§ ACUVUE® Theravision™ with Ketotifen may help people continue to wear their contact lenses for vision correction, and prevent allergic eye itch, without the need for allergy eye drops.
ACUVUE® is the most trusted brand for eye care professionals globally^ and has built a legacy by making contact lenses that are unbeaten in comfort†,, across 47 clinical studies.† ACUVUE® Theravision™ with Ketotifen.